Table 2. Overall survival in NAFLD-HCC vs. non NAFLD-HCC: results of 2 validation cohorts.
| OS/patient background | Cohort 1 (n=130) | P value | Cohort 2 (n=118) | P value | ||||
|---|---|---|---|---|---|---|---|---|
| NAFLD-HCC (n=13) | Non NAFLD-HCC (n=117) | NAFLD-HCC (n=11) | Non NAFLD-HCC (n=107) | |||||
| OS, months (95% CI) | 5.4 (1.8–9.0) | 11.0 (7.5–14.5) | 0.023 | 8.8 (3.6–12.4) | 17. 7 (8.8–26.5) | 0.034 | ||
| Country/region | Australia, Germany, | United States, Europe, | ||||||
| Italy, Switzerland | Taiwan, Japan | |||||||
| Age | 72.5±8.5 | 67.4±8.6 | 0.046 | 67.3±7.5 | 61.9±10.1 | 0.046 | ||
| Child-Pugh Class A | 6 (46%) | 76 (65%) | 0.229 | 11 (100%) | 107 (100%) | |||
| Child-Pugh Class B | 7 (54%) | 41 (35%) | 0 (0%) | 0 (0%) | ||||
| MVI | 3 (23%) | 57 (49%) | 0.079 | 4 (36%) | 30 (28%) | 0.441 | ||
| EHS | 10 (77%) | 78 (67%) | 0.547 | 6 (54%) | 43 (40%) | 0.233 | ||
NAFLD, non-alcoholic fatty liver disease; HCC, hepatocellular carcinoma; NASH, non-alcoholic steatohepatitis; MVI, macrovascular invasion; EHS, extrahepatic spread.